- Home
- INAC vs IKT Comparison
INAC vs IKT Comparison
Compare INAC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAC
- IKT
- Stock Information
- Founded
- INAC 2024
- IKT 2008
- Country
- INAC United States
- IKT United States
- Employees
- INAC N/A
- IKT N/A
- Industry
- INAC
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- INAC
- IKT Health Care
- Exchange
- INAC Nasdaq
- IKT Nasdaq
- Market Cap
- INAC 147.0M
- IKT 123.7M
- IPO Year
- INAC 2025
- IKT 2020
- Fundamental
- Price
- INAC $9.98
- IKT $1.63
- Analyst Decision
- INAC
- IKT Buy
- Analyst Count
- INAC 0
- IKT 2
- Target Price
- INAC N/A
- IKT $8.00
- AVG Volume (30 Days)
- INAC 36.7K
- IKT 138.4K
- Earning Date
- INAC 01-01-0001
- IKT 11-13-2025
- Dividend Yield
- INAC N/A
- IKT N/A
- EPS Growth
- INAC N/A
- IKT N/A
- EPS
- INAC N/A
- IKT N/A
- Revenue
- INAC N/A
- IKT N/A
- Revenue This Year
- INAC N/A
- IKT N/A
- Revenue Next Year
- INAC N/A
- IKT N/A
- P/E Ratio
- INAC N/A
- IKT N/A
- Revenue Growth
- INAC N/A
- IKT N/A
- 52 Week Low
- INAC $9.92
- IKT $1.15
- 52 Week High
- INAC $9.99
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- INAC N/A
- IKT 48.84
- Support Level
- INAC N/A
- IKT $1.57
- Resistance Level
- INAC N/A
- IKT $1.70
- Average True Range (ATR)
- INAC 0.00
- IKT 0.12
- MACD
- INAC 0.00
- IKT 0.01
- Stochastic Oscillator
- INAC 0.00
- IKT 51.61
About INAC Indigo Acquisition Corp. Ordinary Shares
Indigo Acquisition Corp is a blank check company.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.